title: [Pharmacokinetics of carboplatin (CBDCA) and tissue concentration of platinum in gynecologic organs].
abstract: A pharmacokinetics and platinum concentration in the gynecologic organs were measured following the intravenous drip infusion of 375 mg/m2 of CBDCA. Total platinum (TP) in plasma decreased biphasically and free platinum (FP) was almost monophasically eliminated. The t 1/2 of FP was about 51 min. and the percentage of FP out of TP at four hours after administration was more than 92%, which was much higher proportion compared with that of cisplatin (CDDP). A cumulative excretion of platinum in the urine within 24 hours was 69%. The platinum concentration in the benign part of portio and endocervix were higher than that of malignant portion, although there were no significant differences in other pelvic organs such as ovary and tubes. However, pelvic lymph-nodes showed less platinum concentration both in metastatic and non-metastatic tissues. Platinum concentration in the tissue did not change significantly with lapse of time. Bone marrow suppression was observed especially in the patients who had received chemotherapy or radiotherapy. No renal toxicity was observed even without any hydration and gastro-intestinal toxicity was much milder than that of CDDP.
authors.affiliation: Dept. of Obstetrics and Gynecology, Okayama University Medical School.
authors.forename: K
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Y
authors.initials: Y
authors.lastname: Miyagi
authors.forename: R
authors.initials: R
authors.lastname: Hayase
authors.forename: M
authors.initials: M
authors.lastname: Yoshinouchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kobashi
authors.forename: I
authors.initials: I
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Sekiba
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001792:Blood Platelets / Q000378:metabolism; D001806:Blood Urea Nitrogen; D016190:Carboplatin; D002584:Cervix Uteri / Q000378:metabolism; D004912:Erythrocytes / Q000378:metabolism; D005260:Female; D005833:Genital Neoplasms, Female / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics*; D010053:Ovary / Q000032:analysis / Q000378:metabolism*; D010984:Platinum / Q000032:analysis*; D014599:Uterus / Q000032:analysis / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D010984:Platinum; D016190:Carboplatin